The EU’s HTA regulation: Are we ready for kick-off?

On Tuesday 8 October from 15:00-17:30 CEST, the 2024 ECO Community 365 Roundtable series will continue with a spotlight placed on the issue of ‘EU HTA Cooperation’.

 

A landmark piece of European Union legislation to achieve greater cooperation between countries on Health Technology Assessment (HTA) is due to come into force in January 2025, with cancer medicines among the first group of therapies in its focus. Is the EU ready for Joint Clinical Assessments? Have stakeholder views been taken account of? Is there still time to address any remaining concerns? Register and participate in the roundtable to be a part of the conversation.

 

The Roundtable will be co-chaired by Natacha Bolaños, Regional Manager for Europe, Lymphoma Coalition. 

08 October 2024 15:00 - 17:30 CEST

Virtual

 Apply for Registration

community 365 roundtable eu hta cooperation visual 1

Programme

15:00-15:20 Welcome and introductions  

Introductory remarks by:

  • Natacha Bolaños, Regional Manager for Europe, Lymphoma Coalition 
  • Introduction to the HTA regulation and progress so far
15:20-16:00 Session 1: EU level HTA decisions – Who decides and how? 

Presentation on governance and decision-making processes associated to the HTA Regulation, and the results of the Commission consultation on conflict of interest. 

  • Béla Dajka, Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk, Head of European Affairs, European Hematology Association
16:00-16:40 Session 2: How will data be used to support EU level HTA decision-making? 

Session co-chaired by Natacha Bolaños, Regional Manager for Europe, Lymphoma Coalition and Kostas Papadakis, Head of Oncology Market Access, Bayer

Expert discussion with audience and: 

  • Ansgar Hebborn, Roche Pharma's Head of Global HTA & Payment Policy
  • Panos Kanavos, Deputy Director at LSE Health, London School of Economics
  • Sarah Collen, EU Policy Manager, European Association of Urology 
  • Tamara Hussong Milagre, President at EVITA, ePAG Representative at European Reference Network GENTURIS, EUPATI fellow
16:40-17:20 Session 3: Are countries ready for implementing the EU HTA regulation? 

Expert discussion with audience and: 

  • Valentina Strammiello, Director of Strategic Initiatives, European Patients Forum
  • Mihai Rotaru, Director Market Access, EFPIA
17:20-17:30 Closing remarks and summary 

 

More information will be published here soon.

 

Speakers

  • Natacha Bolaños ECO Patient Advisory Committee Member, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
  • Sarah Collen EU Policy Manager, European Association of Urology (EAU)
  • Béla Dajka Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk Head of European Affairs, European Hematology Association
  • Ansgar Hebborn Head of Access Policy Affairs Europe, Roche
show all speakers (11)

Speakers

  • Natacha Bolaños ECO Patient Advisory Committee Member, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
  • Sarah Collen EU Policy Manager, European Association of Urology (EAU)
  • Béla Dajka Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk Head of European Affairs, European Hematology Association
  • Ansgar Hebborn Head of Access Policy Affairs Europe, Roche
show all speakers (11)
  • Natacha Bolaños ECO Patient Advisory Committee Member, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
  • Sarah Collen EU Policy Manager, European Association of Urology (EAU)
  • Béla Dajka Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk Head of European Affairs, European Hematology Association
  • Ansgar Hebborn Head of Access Policy Affairs Europe, Roche
  • Tamara Hussong Milagre President at EVITA, ePAG Representative at European Reference Network GENTURIS, EUPATI fellow
  • Panos Kanavos Deputy Director, LSE Health, London School of Economics
  • Kostas Papadakis Head of Oncology Market Access, Bayer
  • Mihai Rotaru Director Market Access, EFPIA
  • Valentina Strammiello Director of Strategic Initiatives, European Patients Forum

Speakers

  • Natacha Bolaños ECO Patient Advisory Committee Member, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
  • Sarah Collen EU Policy Manager, European Association of Urology (EAU)
  • Béla Dajka Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk Head of European Affairs, European Hematology Association
  • Ansgar Hebborn Head of Access Policy Affairs Europe, Roche
show all speakers (11)

Speakers

  • Natacha Bolaños ECO Patient Advisory Committee Member, Regional Manager for Europe, Lymphoma Coalition
  • Eric Van Cutsem Board Member, European Cancer Organisation, Head of Digestive Oncology, University Hospitals Gasthuisberg & KULeuven
  • Sarah Collen EU Policy Manager, European Association of Urology (EAU)
  • Béla Dajka Health Policy Officer, DG Sante European Commission
  • Robin Doeswijk Head of European Affairs, European Hematology Association
  • Ansgar Hebborn Head of Access Policy Affairs Europe, Roche
show all speakers (11)